Fredy Revilla, MD
Neurology · Greenville, SCNPI 1760418610
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $172,334 of the $208,433 with a category attached, or 82.7%. Teva Pharmaceuticals USA, Inc. accounts for 81.2% of it on its own, with 26 other manufacturers making up the rest. Among neurology clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 300 payments — averaging $694.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$169K
- Lundbeck LLC$18K
- MDD US Operations, LLC$16K
- Kyowa Kirin, Inc.$2K
- Boston Scientific$493
- Abbott$338
- plus $1K from 21 others
Across 318 payments — averaging $843.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$119K
- Neurocrine Biosciences, Inc.$99K
- MDD US Operations, LLC$33K
- Acadia Pharmaceuticals Inc$16K
What the payments were for
- Consulting fees$16,1088%
- Speaking & faculty fees$172,33483%
- Travel & lodging$13,1086%
- Food & beverage$6,8833%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 152 | $169,339 |
| Lundbeck LLC | 22 | $18,377 |
| MDD US Operations, LLC | 37 | $16,142 |
| Kyowa Kirin, Inc. | 5 | $2,260 |
| Boston Scientific | 7 | $493 |
| Abbott | 4 | $338 |
| Amneal Pharmaceuticals LLC | 6 | $336 |
| Neurocrine Biosciences, Inc. | 5 | $207 |
| Acadia Pharmaceuticals Inc | 19 | $187 |
| AbbVie(2 entities) | 8 | $117 |
| Alnylam Pharmaceuticals Inc. | 6 | $95 |
| Sanofi | 3 | $65 |
| Amgen | 3 | $65 |
| Acorda Therapeutics, Inc | 3 | $45 |
| Philips North America LLC | 1 | $45 |
| Avanir Pharmaceuticals, Inc. | 3 | $44 |
| Grifols USA, LLC | 3 | $44 |
| Merz North America, Inc. | 2 | $39 |
| Novartis | 2 | $30 |
| Bausch Health US, LLC | 2 | $28 |
| Aquestive Therapeutics, Inc. | 1 | $25 |
| CSL Behring | 1 | $22 |
| Genentech USA, Inc. | 1 | $21 |
| Revance Therapeutics, Inc. | 1 | $20 |
| Upsher-smith Laboratories LLC | 1 | $19 |
| Livanova USA, Inc. | 1 | $18 |
| Medtronic | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AUSTEDO$114,109
- Austedo XR$53,053
- NORTHERA$18,187
- MYOBLOC$15,175
- Xadago$5,798
- APOKYN$5,798
- NOURIANZ$2,229
- SPECTRA WAVEWRITER$269
- Infinity DBS Pulse Generators$145
- INFINITY$141
- INGREZZA$136
- CREXONT$130
How this compares
$208,433 in reported general payments places this provider in the 95th percentile of 270 neurology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 74 | $451,528 |
| Droxidopa | 63 | $152,989 |
| AustedoDeutetrabenazine | 15 | $99,677 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 402 | $22,987 |
| XadagoSafinamide Mesylate | 13 | $16,494 |
| Entacapone | 70 | $12,499 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 195 | $6,688 |
| RivastigmineRivastigmine Tartrate | 52 | $3,902 |
| Midodrine Hcl | 27 | $2,758 |
| Memantine Hcl | 34 | $2,073 |
| Primidone | 52 | $2,026 |
| AmantadineAmantadine Hcl | 35 | $1,884 |
| Rasagiline Mesylate | 18 | $1,775 |
| Clozapine | 71 | $1,725 |
| Quetiapine Fumarate | 70 | $1,321 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $187 | $451,52874 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $169,339 | $99,67715 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $336 | $1,04911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 270 neurology providers in South Carolina.
Other neurology in Greenville
- Mary HughesGreenville$404K
- Kathleen WoschkolupGreenville$97K
- Sandip JainGreenville$43K
- John AbsherGreenville$30K
- Amber StutzGreenville$26K
- John PorterGreenville$17K
- Brian ThompsonGreenville$11K
- John BakerSumter$779K
- Robert CarlileSummerville$428K
- Jose CardenasAiken$216K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.